News Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
65.27 ^USD	-0.02%		+3.00%	-21.82%

May. 08	Cytokinetics Q1 Net Loss Narrows, Revenue Declines	MT
May. 08	Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Posts Q1 Revenue $835,000, vs. Street Est of $0.9M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cytokinetics Q1 Net Loss Narrows, Revenue Declines	May. 08	MT
Cytokinetics: Q1 Earnings Snapshot	May. 08	AQ
Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Posts Q1 Revenue $835,000, vs. Street Est of $0.9M	May. 08	MT
Cytokinetics Reports First Quarter 2024 Financial Results	May. 08	AQ
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy	May. 08	AQ
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586	May. 08	AQ
Cytokinetics, Incorporated Announces Topline Data from Phase 1 Clinical Study of Ck-4021586	May. 08	CI
Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment	May. 08	CI
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing	May. 07	MT
Cytokinetics to Hold Annual Meeting of Stockholders	May. 07	AQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 02	AQ
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress	Apr. 29	AQ
Cytokinetics Appoints Sung Lee as CFO	Apr. 26	MT
Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024	Apr. 26	CI
Cytokinetics, Incorporated Announces Chief Financial Officer Changes, Effective May 8, 2024	Apr. 26	CI
Cytokinetics to Announce First Quarter Results on May 8, 2024	Apr. 24	AQ
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress	Apr. 10	AQ
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	Apr. 09	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 05	MT
Cytokinetics Reports Positive Follow-On Data for Prospective Heart Medication; Shares Rise	Apr. 05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Summary

Filters